China Invests RMB 200 Million In Engineering Research Center For New Vaccines
This article was originally published in PharmAsia News
Executive SummaryChina National Biotec Group, China CDC's National Institute for Viral Disease Control and Prevention and two other biotech companies recently held a groundbreaking ceremony for their co-funded national engineering research center for new vaccines. With a total investment of over RMB 200 million ($29.3 million), the facility will feature five separate pilot platforms for inactivated viral vaccines, attenuated viral vaccines and bacterial vaccines. When completed by the end of next year, the center will apply modern biotechnology to improve conventional vaccines, tackle key technological problems in new vaccine R&D and commercialization, as well as focus on development and pilots of new vaccines, recombinant proteins, peptide drugs and nucleic acid drugs. (Click here for more - Chinese Language)
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.